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Abstract
Type 2 diabetes (T2D) is more prevalent in African Americans than in Europeans. However, little is known about the genetic
risk in African Americans despite the recent identification of more than 70 T2D loci primarily by genome-wide association
studies (GWAS) in individuals of European ancestry. In order to investigate the genetic architecture of T2D in African
Americans, the MEta-analysis of type 2 DIabetes in African Americans (MEDIA) Consortium examined 17 GWAS on T2D
comprising 8,284 cases and 15,543 controls in African Americans in stage 1 analysis. Single nucleotide polymorphisms
(SNPs) association analysis was conducted in each study under the additive model after adjustment for age, sex, study site,
and principal components. Meta-analysis of approximately 2.6 million genotyped and imputed SNPs in all studies was
conducted using an inverse variance-weighted fixed effect model. Replications were performed to follow up 21 loci in up to
6,061 cases and 5,483 controls in African Americans, and 8,130 cases and 38,987 controls of European ancestry. We
identified three known loci (TCF7L2, HMGA2 and KCNQ1) and two novel loci (HLA-B and INS-IGF2) at genome-wide
significance (4.15610294,P,561028, odds ratio (OR) = 1.09 to 1.36). Fine-mapping revealed that 88 of 158 previously
identified T2D or glucose homeostasis loci demonstrated nominal to highly significant association (2.2610223 , locus-wide
P,0.05). These novel and previously identified loci yielded a sibling relative risk of 1.19, explaining 17.5% of the phenotypic
variance of T2D on the liability scale in African Americans. Overall, this study identified two novel susceptibility loci for T2D
in African Americans. A substantial number of previously reported loci are transferable to African Americans after
accounting for linkage disequilibrium, enabling fine mapping of causal variants in trans-ethnic meta-analysis studies.
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Introduction
The prevalence of type 2 diabetes (T2D) among adults in the
USA is currently 11.3%, with substantially higher prevalence in
African Americans (18.7%) than in European Americans (10.2%)
[1]. To date, genome-wide association studies (GWAS) have
identified .70 susceptibility loci for T2D [2–8]. While it is known
that T2D is heritable in African Americans [9], it is unclear how
much heritability is explained by the known genetic associations
discovered primarily from European ancestry populations and
whether there are risk loci specific to African Americans. Given
that individuals of African ancestry tend to harbor more genetic
diversity than individuals of other ancestries [10], we hypothesized
that large-scale association analyses in African Americans could
shed light on the genetic architecture of T2D and the risk
attributable to cosmopolitan vs. population-specific variants.
Results
Study overview
We conducted a meta-analysis of 17 African American GWAS on
T2D comprising 8,284 cases and 15,543 controls (Tables S1 and
S2). Missing genotypes in individual studies were imputed to one of
the HapMap reference panels (Phase II release 21–24 CEU+YRI,
Phase II release 22 all populations, Phase II+III release 27 CEU+
YRI, Phase II+III release 27 CEU+YRI+ASW or Phase II+III
release 27 all populations) using MACH, IMPUTE2 or BEAGLE
(Table S3). Genomic control corrections [11] were applied to each
study (l=1.01–1.08) and after meta-analysis (l=1.06) due to
modest inflated association results (Table S3) [12]. Association
results for ,2.6M SNPs were subsequently examined.
From stage 1 meta-analysis, 49 SNPs moderately associated
with T2D (P,161025) and two candidate SNPs near the p value
threshold (rs231356 at KCNQ1, P=2.8461025 and rs2244020 at
HLA-B, P=1.0261025) totaling 51 SNPs in 21 loci were followed
up for replication. rs231356 is 14 kb downstream of the reported
T2D index SNP, rs231362, in Europeans [3]. Moderate associ-
ations have also been observed across the HLA region in
Europeans [3]. The stage 2 replication included in silico and de
novo replication in up to 11,544 African American T2D cases and
controls, as well as in silico replication in 47,117 individuals of
European ancestry from DIAGRAMv2 [3] (Table S4). Meta-
analyses were performed to combine results from African
Americans (stage 1+2a, n#35,371, Table S4) and both African
Americans and Europeans (stage 1+2a+2b, n#82,488, Table S4).
T2D loci reaching genome-wide significance
Five independent loci reached genome-wide significance (P,
561028). Stage 1 meta-analysis identified the established TCF7L2
locus. Stage 1+2a meta-analysis identified the established KCNQ1
and HMGA2 loci. Stage 1+2a+2b meta-analysis identified a
second signal at KCNQ1 and a novel HLA-B locus. Secondary
analysis including body mass index (BMI) adjustment in stage 1+
2a meta-analysis identified the second novel locus at INS-IGF2
(Table 1 and Figure 1). None of the most strongly associated SNPs
at these loci demonstrated significant heterogeneity of effect sizes
among studies within each stage, between African Americans in
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stages 1 and 2a, or between African Americans in stage 1+2a and
Europeans in stage 2b after Bonferroni correction of multiple
comparisons (Phet.0.001) (Figure S1).
At the TCF7L2 locus, the most strongly associated SNP in stage
1+2a African Americans samples was rs7903146 (OR=1.33,
P=4.78610244, Table 1 and Figure 2). rs7903146 is also the
index SNP (most significantly associated with T2D in prior studies)
in Europeans (OR=1.40, P=2.21610251) [3], South Asians
(OR=1.25, P=3.4610219) [4] and East Asians (OR=1.48,
P=2.44610215) [13].
Two association signals were observed at KCNQ1 (Table 1 and
Figure 2). The first association signal was represented by rs2283228
located at the 39 end of KCNQ1 (stage 1+2a OR=1.20,
P=9.90610211; stage 1+2a+2b OR=1.19, P=4.87610213).
Using data from individuals of African ancestry in Southwest USA
(ASW) from the 1000 Genomes Project (1KGP) [14], rs2283228
mapped to the same linkage disequilibrium (LD)-based interval as
index SNPs from other populations (rs2283228 [15] and rs2237892
[16–17] in Japanese, rs2237892 in Hispanics [18], rs163182 [19]
and rs2237895 [20] in Han Chinese). The second association signal
was represented by rs231356 (r2=0 with rs2283228 in both ASW
and CEU) (stage 1+2a OR=1.11, P=1.9461025; stage 1+2a+2b
OR=1.09, P=3.9361028), located 144 kb upstream of the first
signal. rs231356 is located at the same LD interval as the index SNPs
rs231362 in Europeans [3] and rs231359 in Chinese [20].
At the HMGA2 locus, the most strongly associated SNP was
rs343092 (stage 1+2a OR=1.16, P=8.7961029; stage 1+2a+2b
OR=1.14, P=2.75610212; Table 1 and Figure 2). rs343092 is
located 76 kb downstream and at the same LD interval as of the
index SNP rs1531343 reported in Europeans [3].
Two novel T2D loci were identified. The effect sizes of
rs2244020 located near HLA-B were similar in African Americans
and Europeans (OR=1.11 vs. 1.07, Phet=0.26; stage 1+2a+2b
P=6.5761029) (Table 1 and Figure 2). HLA-B encodes the class
I major histocompatibility complex involved in antigen presenta-
tion in immune responses.
The most strongly associated SNP near INS-IGF2 was
rs3842770 in African Americans (OR=1.14, P=2.7861028,
stage 1+2a BMI adjusted, Table 1 and Figure 2) but the risk A
allele was absent in the CEU population. Insulin plays a key role in
glucose homeostasis. Mutations at INS lead to neonatal diabetes,
type 1 diabetes, and hyperinsulinemia [21]. Insulin-like growth
factor 2 (IGF2) is involved in growth and development. IGF2
overexpression in transgenic mice leads to islet hyperplasia [22]
and IGF2 deficiency in the Goto–Kakizaki rat leads to beta cell
mass anomaly [23].
Associations at previously reported T2D and glucose
homeostasis loci
We investigated index SNPs from 158 independent loci
associated with T2D and/or glucose homeostasis from prior
genome-wide and candidate gene studies in individuals of
European, East Asian, South Asian, or African American ancestry
(Table S5). Among the 104 T2D-associated index SNPs, 19 were
associated with T2D in stage 1 African American samples (P,
0.05). Most of the 17 T2D-associated SNPs that showed consistent
direction of effects had similar effect sizes between this study and
prior reports, despite that rs10440833 at CDKAL1 had substan-
tially stronger effect size in Europeans (OR=1.25) than in African
Americans (OR=1.06, Phet=5.86610
26). Additionally, 3 out of
54 trait-increasing alleles from glucose homeostasis-associated
index SNPs were associated with increased T2D risk in African
Americans (P,0.05).
We also performed a locus-wide analysis to test for associations
of all SNPs within the LD region at r2$0.3 with the previously
reported index SNPs and results were corrected for the effective
number of SNPs [24]. Since the causal variant(s) at each locus may
be different or reside on different haplotypes across populations
with different LD structures, this approach allows the identifica-
tion of the most strongly associated SNPs in African Americans
that may or may not be in LD with the index SNPs reported in
other populations. A total of 55 T2D- and 29 glucose-associated
loci were associated with T2D in African Americans (Plocus,0.05,
corrected for LD in ASW for SNPs within a locus; Table S6). We
compared the genetic architecture between the previously
reported index SNPs and our fine-mapped SNPs for these 84
loci. The respective average risk allele frequencies were 0.51 and
0.46, and the distributions or pairwise differences of risk allele
frequencies were not significantly different (P=0.255, Wilcoxon
rank sum test; and P=0.295, Wilcoxon signed-rank test,
respectively, Figure S2). In contrast, the average odds ratios for
the risk alleles were higher for the fine-mapped SNPs as compared
to the index SNPs (1.14 vs. 1.05). The distributions and pairwise
differences of risk allele odds ratios were significantly different
(P=1.18610219 and 5.55610214, respectively, Figure S2). Thus,
the locus-wide analysis identified variants with larger effect sizes
and similar allele frequencies.
We leveraged differences in LD between African Americans and
Europeans to fine-map and re-annotate several established loci.
The association signal spanning ,100 kb at INTS8 in African
Americans overlapped the ,200 kb TP53INP1 T2D locus in
Europeans [3]. The most strongly associated SNP in MEDIA
tended to have larger effect size in African Americans than in
Europeans (rs17359493, OR=1.13 vs. 1.06, P=1.3961027 vs.
3.2061022, respectively, Phet=0.06) (Table S4). However,
rs17359493 at intron 10 of INTS8 was only in weak LD with
the reported index SNP rs896854 in Europeans (r2=0.21 in CEU,
0.10 in ASW). Neither the reported index SNP rs896854 nor its
proxies from the CEU data demonstrated significant association to
T2D in African Americans (Table S6 and Figure S3a,b),
suggesting that rs17359493 may be an independent novel signal.
INTS8 encodes a subunit of the integrator complex which is
involved in the cleavage of small nuclear RNAs. At KCNQ1, the
most strongly associated SNP rs231356 was in weak LD with the
Author Summary
Despite the higher prevalence of type 2 diabetes (T2D) in
African Americans than in Europeans, recent genome-wide
association studies (GWAS) were examined primarily in
individuals of European ancestry. In this study, we performed
meta-analysis of 17 GWAS in 8,284 cases and 15,543 controls
to explore the genetic architecture of T2D in African
Americans. Following replication in additional 6,061 cases
and 5,483 controls in African Americans, and 8,130 cases and
38,987 controls of European ancestry, we identified two
novel and three previous reported T2D loci reaching
genome-wide significance. We also examined 158 loci
previously reported to be associated with T2D or regulating
glucose homeostasis. While 56% of these loci were shared
between African Americans and the other populations, the
strongest associations in African Americans are often found
in nearby single nucleotide polymorphisms (SNPs) instead of
the original SNPs reported in other populations due to
differential genetic architecture across populations. Our
results highlight the importance of performing genetic
studies in non-European populations to fine map the causal
genetic variants.
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Table 1. Novel and previously identified loci associated with T2D at P,561028.
Stage 1 GWAS meta-analysis
in in African Americans: up to
8,284 cases and 15,543
controls
Stage 2a replication in
African Americans: up to
6,061 cases and 5,483
controls
Stage 1+2a meta-analysis in
African Americans: up to
14,345 cases and 21,026
controls
Stage 2b
replication in
Europeans
(DIAGRAMv2): up
to 8,130 cases and
38,987 controls
Stage 1+2a+2b meta-
analysis of all African
Americans and Europeans:
up to 22,475 cases and
60,013 controls
Loci Chr
Position
(Build 36) SNP Allelesa RAFb
OR
(95% CI) P Phet
OR
(95% CI) P Phet
OR
(95% CI) P Phet
OR
(95% CI) P
OR
(95% CI) P Phet
Previously identified T2D loci
TCF7L2c 10 114748339 rs7903146 T/C 0.30 1.32
(1.25–1.4)
6.62E-24 1.81E-01 1.34
(1.26–1.43)
8.38E-20 6.01E-03 1.33
(1.28–1.39)
4.78E-44 7.34E-01 1.4
(1.34–1.46)
2.21E-51 1.36
(1.32–1.4)
4.15E-94 1.16E-01
KCNQ1c 11 2661919 rs231356 T/A 0.27 1.14
(1.07–1.21)
2.84E-05 9.11E-01 1.05
(0.98–1.14)
1.68E-01 3.26E-01 1.11
(1.06–1.16)
1.94E-05 1.08E-01 1.08
(1.04–1.13)
4.37E-04 1.09
(1.06–1.13)
3.93E-08 5.27E-01
KCNQ1c 11 2806106 rs2283228 A/C 0.89 1.22
(1.14–1.31)
6.10E-08 9.48E-02 1.17
(1.06–1.28)
1.04E-03 7.10E-01 1.2
(1.14–1.27)
9.90E-11 4.34E-01 1.16
(1.06–1.26)
9.73E-04 1.19
(1.13–1.24)
4.87E-13 4.90E-01
HMGA2c12 64537207 rs343092 T/G 0.81 1.16
(1.09–1.24)
1.91E-06 9.48E-01 1.15
(1.04–1.26)
3.99E-03 3.37E-01 1.16
(1.1–1.22)
8.79E-09 7.93E-01 1.12
(1.06–1.19)
5.43E-05 1.14
(1.1–1.19)
2.75E-12 4.41E-01
Newly identified T2D loci
HLA-Bc 6 31455430 rs2244020 G/A 0.69 1.12
(1.06–1.17)
1.02E-05 2.11E-02 1.1
(0.98–1.22)
1.01E-01 1 1.11
(1.07–1.16)
1.14E-06 7.57E-01 1.07
(1.03–1.12)
7.67E-04 1.09
(1.06–1.13)
6.57E-09 2.55E-01
INS-
IGF2d
11 2135246 rs3842770 A/G 0.23 1.18
(1.11–1.25)
8.18E-08 7.16E-01 1.07
(0.99–1.16)
8.09E-02 7.16E-01 1.14
(1.09–1.19)
2.78E-08 7.37E-02 - - - - -
Abbreviations: Chr, chromosome; SNP, single nucleotide polymorphism; RAF, risk allele frequency; OR, odds ratio for risk allele; CI, confidence interval; Phet, heterogeneity P value.
aAlleles are ordered as risk allele/other allele aligned to the forward strand of NCBI Build 36.
bRisk allele frequency in Stage 1 samples.
cAssociations were performed with adjustment for age, sex, study sites, and study-specific principal components.
dAssociations were performed with adjustment for age, sex, study sites, study-specific principal components and body mass index.
P,561028 are in bold.
doi:10.1371/journal.pgen.1004517.t001
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index SNP rs231362 reported in Europeans [3] (r2=0.24 in CEU
and 0.17 in ASW). Given rs231362 was modestly associated with
T2D in African American (P=0.04) and was in weak LD
(r2=0.21 to 0.46 in CEU) with other associated SNPs in this
region (Table S6 and Figure S3c,d), the results suggest a
refinement of the localization of causal variant(s) to variants in
strong LD with rs231356. At HMGA2, the most strongly
associated SNP rs343092 was in moderate LD with the index
SNP rs1531343 (r2=0.60 in CEU and 0.32 in ASW). Despite
rs1531343 and its proxies in high LD were not associated with
T2D in African Americans (P.0.05), several SNPs in moderate
LD, including rs343092, showed nominal to strong associations
(Table S6 and Figure S3e,f). Trans-ethic fine mapping will be
particularly useful to dissect the causal variant(s) at this locus.
Effect of obesity on T2D susceptibility loci
We investigated the influence of obesity by comparing the stage
1 meta-analysis results with or without adjustment for BMI at the
51 most significantly associated SNPs from the GWAS for follow
up (Tables S4 and S7) and 158 established T2D or glucose
homeostasis index SNPs (Table S5). Association results were highly
similar with and without BMI adjustment (correlation coefficients
were 0.99 for both effect sizes and 2logP values). Of particular
note, FTO is suggested to influence T2D primarily through
modulation of adiposity in Europeans [3,25], but evidence is
contradictory across multiple ethnic groups [26–28]. The index
SNP rs11642841 was not significantly associated with T2D in
African Americans without and with BMI adjustment (P=0.06
and 0.23, respectively) (Table S5). The frequency of the risk A
allele was 0.13 in this study. It had 100% power to detect
association at the reported OR of 1.13 at type 1 error rate of 0.05,
suggesting that FTO is unlikely a key T2D susceptibility gene in
African Americans.
Gene expression and bioinformatics analyses
Among the six genome-wide significant loci (Table 1), we found
no coding variants in the most significantly associated SNPs or
their proxies. These SNPs demonstrated only weak associations
with expression quantitative trait loci (eQTLs) (P.0.001, Table
S8). Examination of the ENCODE data [29] revealed that several
SNPs at TCF7L2, KCNQ1, and HMGA2 were located at protein
binding sites or were predicted to alter motif affinity for
transcription factors implicated in energy homeostasis (Table
S9). The most strongly associated SNP rs7903146 in TCF7L2 is
predicted to alter the binding affinity for a POU3F2 regulatory
motif [30]. POU3F2 is a neural transcription factor that enhances
the activation of genes regulated by corticotropin-releasing
hormone which stimulates adrenocorticotropic hormone (ACTH).
ACTH is synthesized from pre-pro-opiomelanocortin (pre-
POMC) which regulates energy homeostasis. For the 39 signal at
KCNQ1, several tag SNPs are predicted to alter the binding
affinity for regulatory motifs, including SREBP, CTCF and
HNF4A. SREBP is a transcription factor involved in sterol
biosynthesis. CTCF regulates the expression of IGF2 [31].
HNF4A is a master regulator of hepatocyte and islet transcription.
The tag SNP rs2257883 at HMGA2 is predicted to alter the
binding affinity of MEF2, which regulates GLUT4 transcription in
insulin responsive tissues [32].
Discussion
We have performed the largest genetic association analysis to
date for T2D in African Americans. Our data support the
hypothesis that risk for T2D is partly attributable to a large
number of common variants with small effects [7]. We identified
HLA-B and INS-IGF2 as novel T2D loci, the latter specific to
African Americans. We found evidence supporting association for
88 previously identified T2D and glucose homeostasis loci. Taken
together, these 90 loci yielded a sibling relative risk of 1.19. The
phenotypic variance measured on the liability scale is substantially
larger in African Americans than in European Americans (17.5%
vs. 5.7%) [7] due to larger effect sizes upon fine-mapping as well as
higher disease prevalence in African Americans.
The two novel T2D loci, HLA-B and INS-IGF2, have been
implicated in type 1 diabetes (T1D) risk in Europeans [33–35].
One limitation of our study is the lack of autoantibody
measurement. However, our results are unlikely to be confounded
by the presence of misclassified patients. Among diabetic youth
Figure 1. Association results of stage 1 meta-analysis in African Americans in a model adjusted for age, sex, study sites and study-
specific principle components. (A) Manhattan plot. Previously identified loci are denoted in red. Novel loci identified in this study are denoted in
blue. (B) Quantile-quantile plot. The observed P values (y axis) were compared with the expected P values under the null distribution (x axis).
doi:10.1371/journal.pgen.1004517.g001
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aged ,20 years, T2D characterized by insulin resistance without
autoimmunity is more prevalent in African Americans (40.1%)
than in European Americans (6.2%), while African Americans less
often present with autoimmunity and insulin deficiency resembling
T1D compared to European Americans (32.5% vs. 62.9%,
respectively) [36]. Autoimmunity is also uncommon in African
American diabetic adults [37]. Furthermore, associations for T1D
are stronger at HLA class II (HLA-DRB1, -DQA1, and -DQB1)
than HLA class I regions in Europeans [33–34,38–41] (http://
www.t1dbase.org). In African Americans, T1D individuals showed
both shared and unique risk and protective HLA class II
haplotypes as compared to European T1D individuals [42–43].
Figure 2. Regional plots of five previously and newly identified T2D loci in African Americans. Association P values (on a2log10 scale) of
genotyped and imputed SNPs from stage 1 meta-analysis are plotted as a function of genomic position (NCBI Build 36). Plots for HLA-B, TCF7L2,
KCNQ1, and HMGA2 used the model without BMI adjustment whereas plots for INS-IGF2 used the model with BMI adjustment. In each panel, the most
strongly associated SNP from stage 1 and stage 1+2a+2b meta-analysis is denoted by a purple circle and a purple diamond, respectively. The color of
all other SNPs indicates LD with the most strongly associated SNP based on the HapMap 2 YRI data. At KCNQ1, two independent signals are shown.
doi:10.1371/journal.pgen.1004517.g002
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More importantly, these individuals also showed substantially
stronger associations at HLA class II (P,1610225) than class I
regions (P,161025) [42], which is in contradiction with our
finding of stronger associations at HLA class I than class II regions
in T2D individuals (HLA-B, Figure S4). The observed HLA-B
association may be due to LD with nearby causal gene(s) since
there is long range LD in this region. Recently, rs3130501 near
POU5F1 and TCF19 was reported for association with T2D in a
trans-ancestry meta-analysis [8]. rs3130501 was located 211 kb
upstream of rs2244020 and mapped to the same LD interval.
However, the two SNPs were not correlated in both CEU
(D9=0.57, r2=0.05) and ASW (D9=0.68, r2=0.16) from 1KGP
nor strongly associated with T2D in the stage 1 meta-analysis
(P=0.04). Other potential non-HLA candidate genes may include
TNFA which regulates immune and inflammatory response. It has
been hypothesized that activated innate and adaptive immune
cells stimulate release of cytokines such as TNFa and IL-1b, which
promote both systemic insulin resistance and b-cell damage [44].
On the other hand, evidence has implicated T1D loci HLA-DQ/
DR, GLIS3 and INS in the susceptibility of latent autoimmune
diabetes in adults (LADA) and/or T2D [7,34,45–46], while T2D
loci such as PPARG and TCF7L2 was associated with T1D [47]
and LADA [46,48], respectively. More comprehensive studies are
needed to understand the shared and distinct genetic risks in
different forms of diabetes which will facilitate diagnosis and
personalized treatment.
Our results have several implications regarding the genetic
architecture of T2D. First, fine-mapping suggests that currently
known loci explain more of the risk than previously estimated.
Second, the loci conferring the largest risk for T2D appear to act
through regulatory rather than protein-coding changes. Third,
many, but not all, of the previously identified T2D loci are shared
across ancestries. The differential LD structure of African-ancestry
populations at shared loci provides an opportunity for fine mapping
in trans-ethnic meta-analysis. Fourth, the ,2.6M MEDIA SNPs
achieved only 43.3% coverage of the 1KGP ASW common SNPs,
suggesting that risk loci that are specific to African-ancestry
individuals are difficult to discover with the genotyping arrays
being used. Large-scale sequencing studies, such as those focusing
on whole genomes, exomes, and targeted resequencing for
associated non-coding regions, will be necessary to further delineate
the causal variants for T2D risk in African Americans.
Materials and Methods
Samples and clinical characterization
Stage 1 discovery samples included 17 T2D GWAS studies
(ARIC, CARDIA, CFS, CHS, FamHS, GeneSTAR, GENOA,
HANDLS, Health ABC, HUFS, JHS, MESA, MESA Family,
SIGNET-REGARDS, WFSM, FIND, and WHI) with up to
23,827 African American subjects (8,284 cases and 15,543
controls). Stage 2 replication samples included up to 11,544
African American subjects (6,061 cases and 5,483 controls), using
in silico replication of GWAS data from eMERGE and IPM
Biobank and de novo genotyping in IRAS, IRASFS, SCCS, and
WFSM. In general, T2D cases were defined as having at least one
of the following: fasting plasma glucose $126 mg/dl, 2 hour
glucose during oral glucose tolerance test (OGTT) $200 mg/dl,
random glucose $200 mg/dl, oral hypoglycemic agent or insulin
treatment, or physician-diagnosed diabetes. All cases were
diagnosed at $25 years (or age at study $25 years if age at
diagnosis was not available). For cohort studies, individuals who
met the criteria at any of the visits were defined as cases. Controls
with normal glucose tolerance (NGT) were defined by satisfying all
the following criteria: fasting plasma glucose ,100 mg/dl, 2 hour
OGTT,140 mg/dl (if available), no treatment of diabetes, and
age $25 years. For cohort studies, individuals who met the criteria
at all visits were defined as controls. All study participants provided
written informed consent, except for eMERGE that use an opt out
program, and approval was obtained from the institutional review
board (IRB) from the respective local institutions. Detailed
descriptions of the participating studies are provided in Text S1.
Genotyping, imputation and quality control
For stage 1 and 2 GWAS studies, genotyping was performed
with Affymetrix or Illumina genome-wide SNP arrays. Imputation
of missing genotypes was performed using MACH [49],
IMPUTE2 [50] or BEAGLE [51] using HapMap reference
haplotypes. For each study, samples reflecting duplicates, low call
rate, gender mismatch, or population outliers were excluded. In
general, SNPs were excluded by the following criteria: call rate ,
0.95, minor allele frequency (MAF),0.01, minor allele count ,
10, Hardy-Weinberg P-value ,161024, or imputation quality
score ,0.5 (Table S3). For de novo replication studies, genotyping
was performed using the Sequenom MassArray platform (Seque-
nom; San Diego, CA). Sample and SNP quality controls were
performed as with GWAS data.
Statistical analysis
Single SNP association was performed for each study by
regressing T2D case/control status on genotypes. To account for
uncertainty of genotype calls during imputation, genotype
probabilities or dosage were used for association tests in imputed
SNPs. The association tests assumed an additive genetic model
and adjusted for age, sex, study centers, and principal components.
Principal components were included to control for confounding
effects of admixture proportion and population structure.
Secondary analysis with additional adjustment for BMI was
performed for SNPs with P,161025 in stage 1 meta-analysis and
index SNPs previously reported to be associated with T2D or
glucose homeostasis traits. BMI adjustment allows increasing
power to detect T2D loci independent of BMI effect and diminish
associations at T2D loci with effects modulated through BMI.
Logistic regression was used for samples of unrelated individuals.
Generalized estimating equations [52] or SOLAR [53] were used
for samples of related individuals. Association results with extreme
values (absolute beta coefficient or standard error .10), primarily
due to low cell counts resulting from small sample sizes and/or low
minor allele frequencies, were excluded (Table S3).
Meta-analysis
In stage 1, association results were combined by a fixed effect
model with inverse variance weighted method using the METAL
software [12]. Genomic control correction [11] was applied to
each study before meta-analysis, and to the overall results after
meta-analysis. Results from SNPs genotyped in ,10,000 samples
and those with allele frequency difference .0.3 among studies
were excluded. A total of 2,579,389 SNPs were analyzed in the
meta-analysis (Table S3). In stage 2a, association results from
African American replication studies were also combined using a
fixed effect inverse variance weighted method. To assess the
overall effects in African Americans (stage 1+2a) and both African
Americans and Europeans (stage 1+2a+2b), association results
from studies in the respective stages were combined using a fixed
effect inverse variance weighted method. Genome-wide signifi-
cance is declared at P,561028 from the meta-analysis result of all
stages, which has better power than the replication-based strategy
[54].
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Among the 51 SNPs carried forward for replication, heteroge-
neity of effect sizes across studies within each stage was assessed
using Cochran’s Q statistic implemented in METAL. Meta-analysis
results from stages 1 and 2a, stage 1+2a and 2b were used to assess
heterogeneity of effect sizes between discovery and replication stages
in African Americans, and between African Americans and
Europeans, respectively. For SNPs with significant heterogeneous
effect size after multiple comparison corrections (Phet,0.001), meta-
analysis results including studies of all stages assessed by the random
effect model implemented in GWAMA [55] were reported.
Heterogeneous associations may partly due to differences in
ascertainment scheme across studies. For index SNPs reported in
prior studies, assessment of heterogeneity using Cochran’s Q
statistic between prior studies and this study were also reported.
Transferability analysis
Index SNPs associated with T2D or glucose homeostasis traits
from prior GWAS and candidate gene studies were examined for
association with T2D in African Americans (Table S5). For the
index SNP association tests, a per-SNP P value ,0.05 was defined
as significant. In the locus-wide analysis, the boundaries of a locus
were defined by the most distant markers (within 6500 kb) using
the 1KGP CEU data with r2$0.3 with the index SNP. All MEDIA
SNPs within these bounds were examined for association analysis.
All pairwise LD values within each locus were estimated using the
1KGP CEU and ASW data. To estimate the effective number of
SNPs at a locus, we retrieved genotypes from the 1KGP ASW data
for markers present in MEDIA, estimated the sample covariance
matrix from those genotypes, and spectrally decomposed the
covariance matrix [24]. The effective number of SNPs was
estimated using the relationship Neff~
PK
k~1
lk
 2, PK
k~1
l2k
 
,
in which lk is the k
th eigenvalue of the K6K covariance matrix for
the K SNPs in the locus [24]. The per-locus significance level was
defined as 0.05/effective number of SNPs (Table S6). By accounting
for all SNPs within the bounds of LD, the per-locus significance level
is corrected to account for markers in LDwith the index SNP as well
as markers not in LD with the index SNP, thereby potentially
allowing for discovery of new associations at markers not tagged by
the index SNP.
Liability-scale variance explained
For each independent locus, we estimated the sibling relative
risk using the most strongly associated SNP within that locus. Let
pi and yi be the risk allele frequency and the corresponding odds
ratio at the ith SNP, respectively. Assuming the additive genetic
model and independence between SNPs, the contribution to the
sibling relative risk ls for a set of N SNPs is given by
ls~ P
N
i~1
1z
pi 1{pið Þ yi{1ð Þ
2
2 1{pið Þzpiyið Þ
2
 !224
3
5 [56]. Let K be the disease
prevalence. The liability-scale variance h2L explained by the set of
N SNPs is given by h2L~
2 T{T1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1{ T2{T2
1
 
1{ T
v
 q 
vzT2
1
v{Tð Þ
, in
which T~w{1 1{Kð Þ, T1~w
{1
1{lsKð Þ, and v~
z
K
, with w{1
representing the standard normal quantile function and z
representing the standard normal density at T [57].
Coverage
The coverage of MEDIA SNPs to the human genome was
estimated using HaploView [58] via pairwise tagging at the
r2=0.8 threshold. We used all SNPs with minor allele frequencies
$1% in both MEDIA and the 1KGP ASW sequence data.
Coverage was estimated using non-overlapping bins of 1,000
SNPs.
Power analysis
Study power was calculated using the genetic power calculator
[59]. For SNPs with MAF$0.3, our study had .80% power to
detect odds ratios for T2D at OR$1.06 and$1.13 at P,0.05 and
P,561028, respectively, in stage 1 samples under an additive
model. The observed odds ratios among our stage 1 most
significantly associated SNPs with P,161025 ranged from 1.11
to 1.56 (Table S4). Given our African American sample size in
stage 1+2a, our study had .80% power to detect OR$1.1 at P,
561028 at MAF$0.3, thus provided good power to detect
genome-wide significance among the most significantly associated
SNPs using all African American samples. For T2D SNPs
reported from the literature, power was also calculated from the
reported effect size using the risk allele frequency from this study
for stage 1 samples at P,0.05 and P,561028, respectively (Table
S5).
Gene expression analysis
The MuTHER resource (www.muther.ac.uk) includes lympho-
blastoid cell lines (LCLs), skin, and adipose tissue derived
simultaneously from a subset of well-phenotyped healthy female
twins from the TwinsUK adult registry [60]. Whole-genome
expression profiling of the samples, each with either two or three
technical replicates, was performed using the Illumina Human
HT-12 V3 BeadChips (Illumina Inc.) according to the protocol
supplied by the manufacturer. Log2-transformed expression signals
were normalized separately per tissue as follows: quantile
normalization was performed across technical replicates of each
individual followed by quantile normalization across all individ-
uals. Genotyping was performed with a combination of Illumina
arrays (HumanHap300, HumanHap610Q, 1M-Duo, and
1.2MDuo 1M). Untyped HapMap2 SNPs were imputed using
the IMPUTE2 software package. In total, 776 adipose and 777
LCL samples had both expression profiles and imputed genotypes.
Association between all SNPs (MAF.5%, IMPUTE info .0.8)
within a gene or within 1 Mb of the gene transcription start or end
site and normalized expression values were performed with the
GenABEL/ProbABEL packages [61–62] using the polygenic
linear model incorporating a kinship matrix in GenABEL followed
by the ProbABEL mmscore score test with imputed genotypes.
Age and experimental batch were included as cofactors.
Genotype and gene expression in LCL in HapMap samples
were also available [63]. Association of genotypes and gene
expression of transcripts within 1 MB of tested SNPs were
analyzed separately for CEU and YRI populations. The variance
components model implemented in SOLAR was used for
association analysis which accounts for correlation among related
individuals [53].
In this study, we examined the association of the most
significantly associated SNPs from the six genome-wide significant
loci and their proxies (r2$0.8 in ASW) within 1 Mb of the
associated SNPs with cis-expression quantitative trait loci (eQTLs)
in peripheral blood leukocytes (LCL) and adipose tissue (Table S8).
ENCODE data analysis
We examined putative function of non-coding genome-wide
significant SNPs and their proxies within 1 Mb (r2$0.8 in 1KGP
ASW) using HaploReg [30] and RegulomeDB [64]. These
databases interrogated multiple chromatin features from the
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Encyclopedia of DNA Elements (ENCODE) project [29]. High
priority was given to variants annotated as protein-binding via
ChIP-seq, and motif-changing via position weight matrices, with
the respective transcription factors implicated in diabetes patho-
genesis and related biological processes.
Supporting Information
Figure S1 Forest plots of the most strongly associated SNPs at five
previously and newly identified T2D loci in African Americans.
Odds ratio and 95% CIs are presented for individual studies (black
circle and line) and meta-analysis results (red diamond and line). At
KCNQ1, two independent associated SNPs are shown.
(PDF)
Figure S2 (A) Distributions of risk allele frequencies for the
previously reported index SNPs (in black) vs. the MEDIA most
strongly associated SNPs (in red) in African Americans from stage
1 meta-analysis. (B) Distributions of odds ratios for risk alleles of
the index SNPs (in black) vs. the most strongly associated MEDIA
SNPs (in red) in African Americans from stage 1 meta-analysis.
(PDF)
Figure S3 Regional plots of stage 1 meta-analysis association results
in African Americans for the most strongly associated SNPs from this
study and the index SNPs from previous studies. (A–B) INTS8-
TP53INP1 region; (C–D)KCNQ1 region; (E–F)HMGA2 region. (A,
C, E) The most strongly associated SNP in MEDIA is denoted by a
purple circle and a red arrow with LD colored based on the HapMap
2 YRI data. (B, D, F) The index SNP is denoted by a purple circle and
a blue arrow with LD colored based on the HapMap 2 CEU data.
(PDF)
Figure S4 Regional plots of HLA-B and HLA-DQ/DR regions
for (A, C) stage 1 meta-analysis association results in African
Americans and HapMap 2 YRI LD data, and (B, D) stage 3
DIAGRAMv2 results in Europeans using HapMap 2 CEU LD
data. (A, B) The most strongly associated SNP rs2244020 at HLA-
B region from this study is denoted by a purple circle and a red
arrow. (C, D) The index SNP rs9272346 from Burton PR et al
(2007) [65] is denoted by a purple circle and a blue arrow.
(PDF)
Table S1 Design of studies in stage 1 GWAS and stage 2a
replication in African Americans.
(PDF)
Table S2 Clinical characteristics of study samples in stage 1
GWAS and stage 2a replication studies in African Americans.
(PDF)
Table S3 Genotyping methods, quality controls, imputation and
statistical analysis in stage 1 GWAS and stage 2a replication
studies in African Americans.
(PDF)
Table S4 SNPs with P value#161025 from stage 1 GWAS
meta-analysis (BMI unadjusted) selected for stage 2 in silico and de
novo replication in African Americans and in silico replication in
individuals of European ancestry from DIAGRAMv2.
(PDF)
Table S5 Stage 1 GWAS meta-analysis results for index SNPs at
established T2D or glucose homeostasis loci in African Americans.
(PDF)
Table S6 Locus-wide association at established T2D or glucose
homeostasis loci in stage 1 GWASmeta-analysis in African Americans.
(PDF)
Table S7 BMI-adjusted association for SNPs from stage 1
GWAS meta-analysis selected for replication.
(PDF)
Table S8 Expression Quantitative Trait Loci (eQTL) analysis
for the genome-wide significant SNPs for T2D. Results are shown
for suggestive evidence of cis-association (P,0.05) between the
genome-wide significant SNPs and their proxies with the genes
within 1 Mb of the associated SNPs.
(PDF)
Table S9 Putative regulatory SNPs predicted from the EN-
CODE project for the genome-wide significant SNPs and their
proxies at TCF7L2, INS-IGF2, KCNQ1 and HMGA2.
(PDF)
Text S1 Description of GWAS and replication studies.
(PDF)
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